All In Biotech

Drug Trial Radar · NCT05096481

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 18, 2024

Primary completion

Jun 15, 2028

Study completion Jun 15, 2030

Sponsor

Lead sponsor
Nationwide Children's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Duke University
First posted
Oct 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51. Funding Source - FDA OOPD

Conditions

  • High Grade Glioma
  • Diffuse Intrinsic Pontine Glioma
  • Recurrent Medulloblastoma

Interventions

  • PEP-CMVBiological

    The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

  • TemozolomideDrug

    Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1

  • Tetanus Diphtheria VaccineBiological

    Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 4-mo PFS in patients with recurrent medulloblastomaTime frame: 4 months
  2. 1-yr OS in patients with newly diagnosed DIPGTime frame: one year
  3. 1-yr PFS in patients with newly diagnosed HGGTime frame: one year

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Not yet recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • C.S. Mott Children's Hospital

    Ann Arbor, Michigan · Recruiting

  • St. Louis Children's Hospital

    St Louis, Missouri · Recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Not yet recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.